-

Five Prime Therapeutics to Participate in the Cowen 41st Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. (NASDAQ: FPRX) today announced that Tom Civik, President and Chief Executive Officer, and Helen Collins, M.D., Executive Vice President and Chief Medical Officer are scheduled to participate in a fireside chat at the Cowen 41st Annual Health Care Conference on Thursday, March 4, 2021 at 10:30 a.m. ET / 7:30 a.m. PT.

Live audio webcast of the presentation will be accessible and available for replay from the “Events & Presentations” section of the Company’s website at: http://investor.fiveprime.com/events.cfm. Five Prime will maintain an archived replay of the webcast on its website for 30 days after the conference.

About Five Prime Therapeutics

Five Prime is a clinical stage biotechnology company relentlessly focused on rewriting cancer. By tackling the tough scientific questions and untapped pathways, we aim to offer new hope by developing novel, breakthrough therapies that have potential to alter the course of disease in cancers with few treatment options. This vision is what defines us and guides our research, clinical development and partnerships. To build a better tomorrow for people with cancer, we are teaming up with patients, physicians, scientists, and industry partners to make a meaningful difference in patients’ lives. Five Prime collaborates with leading global pharmaceutical companies and has therapies in pre-clinical and clinical development. For more information, please visit www.fiveprime.com.

Source: Five Prime Therapeutics, Inc.

Contacts

Media and Investor Contact
Martin Forrest
VP, Investor Relations & Corporate Communications
Five Prime Therapeutics, Inc.
415-365-5625
martin.forrest@fiveprime.com

Five Prime Therapeutics, Inc.

NASDAQ:FPRX

Release Summary
Five Prime Therapeutics to Participate in the Cowen 41st Annual Health Care Conference
Release Versions

Contacts

Media and Investor Contact
Martin Forrest
VP, Investor Relations & Corporate Communications
Five Prime Therapeutics, Inc.
415-365-5625
martin.forrest@fiveprime.com

More News From Five Prime Therapeutics, Inc.

Five Prime Cancels Fourth Quarter and Full-Year 2020 Financial Results Conference Call

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Cancels Fourth Quarter and Full-Year 2020 Financial Results Conference Call...

Amgen to Acquire Five Prime Therapeutics for $1.9 Billion in Cash

THOUSAND OAKS, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--AMGEN TO ACQUIRE FIVE PRIME THERAPEUTICS FOR $1.9 BILLION IN CASH...

Five Prime Therapeutics Announces Timing of Its Fourth Quarter 2020 and Full Year Results Conference Call

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics Announces Timing of Its Fourth Quarter 2020 and Full Year Results Conference Call...
Back to Newsroom